Post on 22-Feb-2016
description
Optimizing Dose Intensity of Treatment for Patients With Metastatic Renal Cell Carcinoma
Activity Goals
Outline
VEGF TKIs for mRCC
Case 1
Case 1: Treatment Options
Case 1: Enrolled in a Clinical Trial
Case 1 (cont)
Case 2
Case 2 (cont)
Early Adverse Effects of TKIs
Late Adverse Effects of TKIs
Management Strategies for Hand-Foot Skin Reaction
Management Strategies for Hand-Foot Skin Reaction (cont)
Management Strategies for Hand-Foot Skin Reaction (cont)
Management of Hypertension
Management of Hypertension (cont)
Gastrointestinal SymptomsNausea/Dyspepsia/Diarrhea Management
Stomatitis and Cheilitis: Mouth
Hair Depigmentation/Skin Discoloration
Hypothyroidism
Fatigue Assessment
Sunitinib: Drug Interactions
Case 3
Case 3 (cont)
Rationale for Individualized Dose/Schedule Changes
Dose-Limiting Toxicities
Improved PFS and OS in Patients With Sunitinib-Related Toxicity
Clinical Outcomes in Patients With mRCC Who Were Treated With Alternative Schedules
Individualizing Sunitinib Therapy
Abbreviations
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)